<DOC>
	<DOCNO>NCT02878057</DOCNO>
	<brief_summary>The treatment patient recurrent metastatic breast cancer remain major problem . There still lack effective targeted therapy Her-2 negative breast cancer.Based present research anti-angiogenesis drug advance breast cancer , investigator believe necessary explore efficacy safety apatinib advance breast cancer .</brief_summary>
	<brief_title>Multicenter Phase II Study Apatinib Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>With comprehensive treatment breast cancer wildly use clinical practice , life quality patient breast cancer improve greatly , survival patient extend well . However , treatment patient recurrent metastatic breast cancer remain major problem . There still lack effective targeted therapy Her-2 negative breast cancer . Based present research anti-angiogenesis drug advance breast cancer , investigator believe necessary explore efficacy safety apatinib advance breast cancer . The aim research evaluate progression-free survival ( PFS ) patient HER-2 negative advanced breast cancer chest wall metastasis treatment apatinib .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . HER2 negative advance breast cancer chest wall metastasis confirm histology cytological examination ( patient receive anthracyclines and/or paclitaxel adjuvant chemotherapy ) . 2 . Patients recurrence metastasis receive two line chemotherapy . 3 . If hormone receptor positive , endocrine therapy must perform patient recurrence metastasis , recurrence metastasis occur less two year endocrine therapy . 4 . â‰¥ 18 year old . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 6 . A life expectancy 3 month . 7 . At least one measurable site disease confirm CT MRI accord Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 criterion require . 8 . If target lesion lymph node , short diameter require less 1.5cm target lesion suitable surgical treatment ; target lesion radiotherapy recur radiation field . 9 . Baseline blood routine examination accordance follow criterion : neutrophil count 1.5*109/L ; platelet count great 100*109/L ; hemoglobin great 9 g/dL ( blood transfusion allow achieve maintain index ) 10 . Liver function accordance follow criterion : total bilirubin le 1.5 time upper limit normal value ; aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) less 2.5 time upper limit normal value , less 5 time upper limit normal value patient liver metastasis . 11 . Renal function accordance follow criterion : serum creatinine less 1.25 time upper limit normal value , creatinine clearance rate calculate great 50 mL/min ; 12 . Women fertility willing take contraceptive measure trial : seven day drug delivery serum urine pregnancy test negative . 1. receive radiation therapy 28 day enrol . Radiotherapy enrollment relieve metastatic bone pain allow , medullary bone radiate exceed 30 % total amount ; 2. symptomatic central nervous system metastases ; 3. current recent ( 30 day enrollment ) use another study drug involve another clinical study ; 4 . Other malignant tumor occur within 5 year ( except cure wellcontrolled cervical carcinoma situ , skin squamous cell carcinoma , skin basal cell carcinoma ) ; 5 . With hypertension blood pressure reduce normal range antihypertensive drug treatment ( systolic blood pressure great equal 140 mmHg diastolic blood pressure great equal 90 mmHg ) . 6 . With grade II high myocardial ischemia myocardial infarction , poorly control arrhythmia ( include QTc interval equal 450 m men , equal 470 m female ) ; 7. accord criterion NYHA , cardiac insufficiency grade III IV leave ventricular ejection fraction ( LVEF ) less 50 % reveal echocardiography ; 8. abnormal coagulation function ( INR &gt; 1.5 prothrombin time ( PT ) &gt; ULN+4 second APTT &gt; 1.5 time ULN ) , bleed tendency thrombolysis anticoagulation therapy ; 9. within 3 month enrollment , clinically significant bleeding symptom occur , obvious bleeding tendency , gastrointestinal bleeding , bleed gastric ulcer , occult blood + + baseline period , suffer vasculitis , et al ; 10. within 4 month enrollment receive major surgery get severe traumatic injury , fracture ulcer ; 11. factor affect absorption oral drug obviously , inability swallow , chronic diarrhea intestinal obstruction , et al ; 12. urine routine test urinary protein ++ , 24 hour urinary protein 1.0 g ; 13. symptomatic serous cavity effusion , need surgically manage ( include pleural effusion , ascites , pericardial effusion ) ; 14. possible condition affect clinical research evaluation result judge researcher .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Apatinib</keyword>
	<keyword>HER-2 Negative</keyword>
	<keyword>Chest wall Metastasis</keyword>
	<keyword>Multicenter Phase II Study</keyword>
	<keyword>Breast cancer</keyword>
</DOC>